Clinical trial
Defendor Special: A Multicenter Prospective Observational Post-registration Study of Combined Chemotherapy With Empegfilrastim Support to Evaluate Safety and Efficacy in Patients With High and "Gray Zone" Risk Reccurrence Breast Cancer, Gastointestinal Cancers and Gynecological Malignancies
NCT04905329 is registered in ClinicalTrials.gov with Moscow Clinical Scientific Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Defendor Special: A Multicenter Prospective Observational Post-registration Study of Combined Chemotherapy With Empegfilrastim Support to Evaluate Safety and Efficacy in Patients With High and "Gray Zone" Risk Reccurrence Breast Cancer, Gastointestinal Cancers and Gynecological Malignancies
- Lead sponsor
- Moscow Clinical Scientific Center
- Phase
- Observational
- Overall status
- Unknown status
- Start date
- April 28, 2020
- Completion date
- September 1, 2023
- Enrollment
- 285 (estimated)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.
breast cancer, gastrointestinal cancer, gynecological malignancies, high-risk cancer, myelosuppression, solid tumor